Albany Molecular Research (AMRI) Receives $4M Milestone Payment From Bristol-Myers
More News related to AMRI
- Jefferies & Co Downgrades Albany Molecular Research (AMRI) to Underperform
- Albany Molecular Research (AMRI) Settles Patent Infringement Litigation Involving Allegra(R)
- AMRI Announces Agreement with Teva Pharmaceuticals and Barr Laboratories to Settle Litigation in ALLEGRA(R) and ALLEGRA(R)D-12 U.S. Patent Dispute
- Morning Movers 11/06: Las Vegas Sands (LVS) Sinks On Filing; Whole Foods (WFMI) Higher
- After-Hours Movers 11/05: Cisco (CSCO) Lower On Guidance, Activision Blizzard (ATVI) Up On Results
More News related to BMY
- XplosiveStocks.com: COP, UST, BMY, WFT, MS, CVX Hot Stocks on the Move
- BridgewaterEquity.com Free Fundamental Sector & Market Research on DB, HRB, BMY and SPF
- Bristol-Myers Squibb (BMY) Declares $0.31/Sh Qtr Dividend, Yielding 4.2%
- Bristol-Myers Squibb Announces Dividend
- Beacon Equity Issues Technical Trade Alerts on Drug Manufacturers: BMY, JNJ, PFE, NVS, GSK, ABT
More News related to FDA
- Standard & Poor's Lowers Ratings on PNC Financial (PNC)
- DA Davidson Downgrades Cascade (CAE) to Underperform
- BMO Downgrades F5 Networks (FFIV) to Market Perform
- Sterne Agee Downgrades EZCorp (EZPW) to Neutral
- CL King Downgrades Steven Madden (SHOO) to Neutral
Albany Molecular Research (NASDAQ: AMRI) said it will receive a $4 million milestone payment from Bristol-Myers Squibb Company (NYSE: BMY) as a result of Bristol-Myers Squibb's submission of a Clinical Trial Application (CTA) to the Health Products and Food Branch (HPFB), Health Canada for approval to initiate Phase I studies on an AMRI compound exclusively licensed to Bristol-Myers Squibb. Upon approval of the CTA by Health Canada, Bristol-Myers Squibb may begin Phase I testing in Canada.
Related Categories
FDAStocks Mentioned
-0.17Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
